Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors.

Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/

Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during the Wrongdoing Period, DexCom and certain of the company’s senior executive officers made a series of materially false and misleading statements to investors about DexCom’s central product – a device it sold to diabetes patients to monitor their blood sugar – the G7 “continuous glucose monitoring” system (“CGM”).

As detailed in the complaint, the defendants are alleged to have “misleadingly touted the G7 as the ‘most accurate CGM cleared by the FDA’ even though they had secretly switched out a critical component of the device without FDA approval and knew from their own testing that the resulting device ‘was worse’ than the original in ‘every accuracy metric.’” When the truth was revealed in a series of partial corrective disclosures, DexCom lost half of its market capitalization.

The investigation seeks to determine whether the members of DexCom’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

DexCom shareholders who purchased or acquired their DXCM shares prior to January 8, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at abell@kaskelalaw.com, or online at:

https://kaskelalaw.com/case/dexcom-inc/

ABOUT KASKELA LAW:

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.

This communication may constitute attorney advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260723834326/en/

The investigation seeks to determine whether the members of DexCom’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.